Uncategorized
Microplasmin Meets Primary Endpoint in Two Phase 3 Trials for Vitreomacular Adhesion
A single injection of microplasmin (ThromboGenics
NV) for the nonsurgical treatment of vitreomacular adhesion
(VMA) performed well in two phase 3 trials, referred
to as MIVI-TRUST, according to presenters at the ASRS.
Both trials were multicenter, randomized, placebo controlled,
and double-masked. In both trials, 326 p...